Rat or Mouse Cancer Bioassay—or None of the Above?

Alden CL , Smith PF , Piper CE and Brej L. (1996). Commentary: A critical appraisal of the value of the mouse cancer bioassay in safety assessment. Toxicol. Pathol. 24: 722-725.

Bernstein L. , Gold LS , Ames BN , Pike MC and Hoel, DG (1985). Some tautologous aspects of the comparison of carcinogenic potency in rats and mice. Fund. Appl. Toxicol. 5: 79-87.

Butterworth BE , Conolly RB and Morgan KT (1995). A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments . Cancer Letters 93: 129-146.

Davies, TS and Monro A. (1995). Marketed human pharmaceuticals reported to be tumorigenic in rodents. J. Am. Coll. Toxicol. 14: 90-107.

Environmental Protection Agency (1996). Proposed Guidelines for Carcinogen Risk Assessment. Environmental Protection Agency, Washington, D.C.

Gaylor DW and Gold LS (1995). Quick estimate of the regulatory virtually safe dose based on the maximum tolerated dose for rodent bioassays. Reg. Toxicol. Pharmacol. 22: 57-63.

Maronpot R. and Boorman GA (1996). The contribution of the mouse in hazard identification studies. Toxicol. Pathol. 24: 726-731.

Scheuplein RJ (1995). Use of "secondary mechanism" in the regulation of carcinogens: A chronology. Cancer Letters 93: 103-112.

Vainio H , Magee P , McGregor D , and McMichael AJ (eds) (1992). Mechanisms of Carcinogenesis in Risk Identification. The International Agency for Research in Cancer, Lyon, France. 615 pp.